Jovicich Jorge, Barkhof Frederik, Babiloni Claudio, Herholz Karl, Mulert Christoph, van Berckel Bart N M, Frisoni Giovanni B
Center for Mind/Brain Sciences, University of Trento, Trento, Italy.
Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
Alzheimers Dement (Amst). 2019 Jan 10;11:69-73. doi: 10.1016/j.dadm.2018.11.005. eCollection 2019 Dec.
Molecular, functional, and structural neuroimaging biomarkers are largely used to study neurodegenerative diseases, but their benefits to patients/science might be greatly enhanced by improving standardization and cross-validation. In this EU Joint Programme-Neurodegenerative Diseases Research-funded project, we surveyed the neuroimaging community to assess perceived barriers in multicentric neuroimaging harmonization and actions to overcome them.
An anonymous survey addressed researchers, clinicians, pharma industry, and professional associations, inquiring about both general and modality-specific harmonization barriers.
Survey participants (459) represented an international (37 countries) multidisciplinary community. We identified two sets of funding actions, one proposing the creation of an updated hub of documents to help researchers plan and execute multicentric neuroimaging studies capitalizing from previous studies, and the other focused on modality-specific harmonization challenges in future neurodegenerative diseases clinical trials.
This large survey of priorities and actions may help define harmonization calls launched by worldwide science funding agencies.
分子、功能和结构神经影像生物标志物在很大程度上用于研究神经退行性疾病，但通过改进标准化和交叉验证，它们对患者/科学的益处可能会大大增强。在这个由欧盟联合计划-神经退行性疾病研究资助的项目中，我们对神经影像学界进行了调查，以评估多中心神经影像协调中存在的感知障碍以及克服这些障碍的行动。
一项匿名调查针对研究人员、临床医生、制药行业和专业协会，询问了一般和特定模态的协调障碍。
调查参与者（459人）代表了一个国际（37个国家）多学科群体。我们确定了两组资助行动，一组提议创建一个更新的文档中心，以帮助研究人员利用以前的研究来规划和执行多中心神经影像研究，另一组则关注未来神经退行性疾病临床试验中特定模态的协调挑战。
这项对优先事项和行动的大规模调查可能有助于确定全球科学资助机构发起的协调呼吁。
